Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Alferminogene-tadenovec (Primary)
- Indications Angina pectoris
- Focus Registrational; Therapeutic Use
- Acronyms AFFIRM
- Sponsors Angionetics
- 18 Jul 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 18 Jul 2022 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 18 Jul 2022 Planned initiation date changed from 1 Jan 2022 to 1 Jan 2023.